Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H1 2017 Summary Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 25 molecules. Out of which approximately 25 molecules are developed by Companies.The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 3, 12 and 5 respectively. Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Ulcerative Colitis, Alopecia, Atopic Dermatitis, Autoimmune Disorders, Psoriasis, Diffuse Large B-Cell Lymphoma, Inflammation, Vitiligo, Allergic Conjunctivitis, Androgenic Alopecia, Asthma, Auto Inflammatory Disease, B-Cell Non-Hodgkin Lymphoma, Cachexia, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Lymphocytic Leukemia (CLL), Cutaneous T-Cell Lymphoma, Dermatitis, Dermatomyositis, Follicular Lymphoma, Heart Transplant Rejection, Inflammatory Bowel Disease, Mantle Cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Pruritus, Psoriatic Arthritis, Refractory Chronic Lymphocytic Leukemia (CLL), Respiratory Tract Inflammatory Disorders, Sarcopenia, Skin Inflammation, Systemic Lupus Erythematosus, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Waldenstrom Macroglobulinemia. The latest report Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects - The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development Aclaris Therapeutics Inc Advinus Therapeutics Ltd Arrien Pharmaceuticals LLC Astellas Pharma Inc Bristol-Myers Squibb Company Chipscreen Biosciences Ltd Clevexel Pharma SAS F. Hoffmann-La Roche Ltd Japan Tobacco Inc Merck & Co Inc MYOS RENS Technology Inc Pfizer Inc Portola Pharmaceuticals Inc Simcere Pharmaceutical Group Theravance Biopharma Inc Vectura Group Plc Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles ARN-4079 - Drug Profile Product Description Mechanism Of Action R&D Progress ATI-50001 - Drug Profile Product Description Mechanism Of Action R&D Progress ATI-50002 - Drug Profile Product Description Mechanism Of Action R&D Progress ATI-50003 - Drug Profile Product Description Mechanism Of Action R&D Progress cerdulatinib - Drug Profile Product Description Mechanism Of Action R&D Progress CS-510 - Drug Profile Product Description Mechanism Of Action R&D Progress CS-944X - Drug Profile Product Description Mechanism Of Action R&D Progress CVXL-0074 - Drug Profile Product Description Mechanism Of Action R&D Progress JTE-052 - Drug Profile Product Description Mechanism Of Action R&D Progress OST-122 - Drug Profile Product Description Mechanism Of Action R&D Progress peficitinib hydrobromide - Drug Profile Product Description Mechanism Of Action R&D Progress PF-06651600 - Drug Profile Product Description Mechanism Of Action R&D Progress PNQ-401 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit JAK2 and JAK3 for Oncology and Auto Immune Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit JAK3 for Autoimmune Diseases and Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Janus Kinase 3 for Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress SNA-125 - Drug Profile Product Description Mechanism Of Action R&D Progress TD-1473 - Drug Profile Product Description Mechanism Of Action R&D Progress TD-3504 - Drug Profile Product Description Mechanism Of Action R&D Progress tofacitinib citrate - Drug Profile Product Description Mechanism Of Action R&D Progress VR-588 - Drug Profile Product Description Mechanism Of Action R&D Progress Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones Featured News & Press Releases May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis May 03, 2017: Pfizer Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Adult Patients With Active Psoriatic Arthritis May 03, 2017: Phase 3 Octave Studies Of Oral Tofacitinib In Ulcerative Colitis Results Published In The New England Journal Of Medicine Mar 27, 2017: XELJANZ Receives Marketing Authorisation In The European Union For The Treatment Of Moderate To Severe Active Rheumatoid Arthritis Mar 15, 2017: Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis Mar 13, 2017: European League Against Rheumatism (EULAR) Includes Janus Kinase (JAK) Inhibitors in Updated Recommendations for the Management of RA Mar 04, 2017: Pfizer to Present Psoriatic Arthritis Data at American Academy of Dermatology Annual Meeting Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization Feb 16, 2017: Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ (tofacitinib citrate) Compared to Humira (adalimumab) Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization Jan 27, 2017: Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis Dec 07, 2016: Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis Nov 28, 2016: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Aclaris Therapeutics Inc, H1 2017 Pipeline by Advinus Therapeutics Ltd, H1 2017 Pipeline by Arrien Pharmaceuticals LLC, H1 2017 Pipeline by Astellas Pharma Inc, H1 2017 Pipeline by Bristol-Myers Squibb Company, H1 2017 Pipeline by Chipscreen Biosciences Ltd, H1 2017 Pipeline by Clevexel Pharma SAS, H1 2017 Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Pipeline by Japan Tobacco Inc, H1 2017 Pipeline by Merck & Co Inc, H1 2017 Pipeline by MYOS RENS Technology Inc, H1 2017 Pipeline by Pfizer Inc, H1 2017 Pipeline by Portola Pharmaceuticals Inc, H1 2017 Pipeline by Simcere Pharmaceutical Group, H1 2017 Pipeline by Theravance Biopharma Inc, H1 2017 Pipeline by Vectura Group Plc, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1), H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
